{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:43:44Z","timestamp":1793497424295,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03512-8","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:19:22Z","timestamp":1773130762000},"page":"1873-1890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhaled Corticosteroid\/Long-Acting \u03b22-Agonist Selection for Patients with Moderate-to-Severe Asthma: Considerations for Real-World Practice, A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"given":"John D.","family":"Blakey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony D.","family":"D\u2019Urzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"3512_CR1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2025. https:\/\/ginasthma.org\/2025-gina-strategy-report\/. Accessed 17 Feb 2026."},{"issue":"5","key":"3512_CR2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1183\/09031936.00074905","volume":"28","author":"H Derendorf","year":"2006","unstructured":"Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042\u201350. https:\/\/doi.org\/10.1183\/09031936.00074905.","journal-title":"Eur Respir J"},{"issue":"11","key":"3512_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008554","volume":"5","author":"YK Loke","year":"2015","unstructured":"Loke YK, Gilbert D, Thavarajah M, Blanco P, Wilson AM. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open. 2015;5(11):e008554. https:\/\/doi.org\/10.1136\/bmjopen-2015-008554.","journal-title":"BMJ Open"},{"key":"3512_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108960","volume":"236","author":"W Shang","year":"2022","unstructured":"Shang W, Wang G, Wang Y, Han D. The safety of long-term use of inhaled corticosteroids in patients with asthma: a systematic review and meta-analysis. Clin Immunol. 2022;236:108960. https:\/\/doi.org\/10.1016\/j.clim.2022.108960.","journal-title":"Clin Immunol"},{"issue":"8","key":"3512_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/thx.2009.128504","volume":"65","author":"KR Chapman","year":"2010","unstructured":"Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010;65(8):747\u201352. https:\/\/doi.org\/10.1136\/thx.2009.128504.","journal-title":"Thorax"},{"issue":"4","key":"3512_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/thoraxjnl-2013-203600","volume":"69","author":"ED Bateman","year":"2014","unstructured":"Bateman ED, O\u2019Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)\/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312\u20139. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-203600.","journal-title":"Thorax"},{"issue":"3","key":"3512_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/thx.2006.066837","volume":"62","author":"J Travers","year":"2007","unstructured":"Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219\u201323.","journal-title":"Thorax"},{"issue":"1","key":"3512_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.rmed.2004.03.026","volume":"99","author":"K Herland","year":"2005","unstructured":"Herland K, Akselsen JP, Skj\u00f8nsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger \u201creal life\u201d population of patients with obstructive lung disease? Respir Med. 2005;99(1):11\u20139.","journal-title":"Respir Med"},{"key":"3512_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01444-2018","author":"T Brown","year":"2018","unstructured":"Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J. 2018;52(6):1801444. https:\/\/doi.org\/10.1183\/13993003.01444-2018.","journal-title":"Eur Respir J"},{"issue":"4","key":"3512_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s12325-022-02410-z","volume":"40","author":"C Domingo","year":"2023","unstructured":"Domingo C, Singh D. The changing asthma management landscape and need for appropriate SABA prescription. Adv Ther. 2023;40(4):1301\u201316. https:\/\/doi.org\/10.1007\/s12325-022-02410-z.","journal-title":"Adv Ther"},{"key":"3512_CR11","unstructured":"National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN). 2024. https:\/\/www.nice.org.uk\/guidance\/ng245. Accessed 17 Feb 2026."},{"issue":"20","key":"3512_CR12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","volume":"378","author":"ED Bateman","year":"2018","unstructured":"Bateman ED, Reddel HK, O\u2019Byrne PM, et al. As-need budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1715275.","journal-title":"N Engl J Med"},{"issue":"1","key":"3512_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jacig.2022.09.006","volume":"2","author":"AHY Chan","year":"2022","unstructured":"Chan AHY, Katzer CB, Pike J, Small M, Horne R. Medication beliefs, adherence, and outcomes in people with asthma: the importance of treatment beliefs in understanding inhaled corticosteroid nonadherence-a retrospective analysis of a real-world data set. J Allergy Clin Immunol Glob. 2022;2(1):51\u201360. https:\/\/doi.org\/10.1016\/j.jacig.2022.09.006.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"8","key":"3512_CR14","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1007\/s12325-024-02900-2","volume":"41","author":"B Aggarwal","year":"2024","unstructured":"Aggarwal B, Al-Moamary M, Allehebi R, et al. APPaRENT 3: asthma patients\u2019 and physicians\u2019 perspectives on the burden and management of asthma in seven countries. Adv Ther. 2024;41(8):3089\u2013118. https:\/\/doi.org\/10.1007\/s12325-024-02900-2.","journal-title":"Adv Ther"},{"issue":"4","key":"3512_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00076-2018","volume":"4","author":"P Katsaounou","year":"2018","unstructured":"Katsaounou P, Odemyr M, Spranger O, et al. Still fighting for breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res. 2018;4(4):00076-2018. https:\/\/doi.org\/10.1183\/23120541.00076-2018.","journal-title":"ERJ Open Res"},{"issue":"6","key":"3512_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.jaci.2014.08.015","volume":"135","author":"ED Bateman","year":"2015","unstructured":"Bateman ED, Buhl R, O\u2019Byrne PM, et al. Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations. J Allergy Clin Immunol. 2015;135(6):1457-64.e4. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.015.","journal-title":"J Allergy Clin Immunol"},{"key":"3512_CR17","unstructured":"NZ Respiratory Guidelines. Asthma + Respiratory Foundation of New Zealand. NZ Adolescent & Adult Asthma Guidelines. 2020. https:\/\/www.nzrespiratoryguidelines.co.nz\/adultguidelines.html. Accessed 17 Feb 2026."},{"issue":"6","key":"3512_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","volume":"146","author":"MM Cloutier","year":"2020","unstructured":"Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the Asthma Management Guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217\u201370. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.003.","journal-title":"J Allergy Clin Immunol"},{"key":"3512_CR19","unstructured":"National Asthma Council. National Asthma Council Australia. Australian Asthma Handbook. Melbourne: National Asthma Council Australia. 2020. https:\/\/www.asthmahandbook.org.au\/. Accessed 17 Feb 2026."},{"issue":"1","key":"3512_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13052-018-0481-1","volume":"44","author":"L Indinnimeo","year":"2018","unstructured":"Indinnimeo L, Chiappini E, Miraglia Del Giudice M. Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics. Ital J Pediatr. 2018;44(1):46. https:\/\/doi.org\/10.1186\/s13052-018-0481-1.","journal-title":"Ital J Pediatr"},{"issue":"2","key":"3512_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.alit.2023.02.006","volume":"72","author":"A Niimi","year":"2023","unstructured":"Niimi A, Fukunaga K, Taniguchi M, et al. Executive summary: Japanese guidelines for adult asthma (JGL) 2021. Allergol Int. 2023;72(2):207\u201326. https:\/\/doi.org\/10.1016\/j.alit.2023.02.006.","journal-title":"Allergol Int"},{"issue":"4","key":"3512_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2023.100277","volume":"5","author":"V Plaza Moral","year":"2023","unstructured":"Plaza Moral V, Alobid I, \u00c1lvarez Rodr\u00edguez C, et al. GEMA 5.3. Spanish guideline on the management of asthma. Open Respir Arch. 2023;5(4):100277. https:\/\/doi.org\/10.1016\/j.opresp.2023.100277.","journal-title":"Open Respir Arch"},{"issue":"3","key":"3512_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaip.2023.10.027","volume":"12","author":"NS Arora","year":"2024","unstructured":"Arora NS, Zhou S, Baptist AP. Regulatory and insurance challenges must be overcome in the United States to meet global standards for asthma management. J Allergy Clin Immunol Pract. 2024;12(3):624\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2023.10.027.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3512_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.18773\/austprescr.2024.046","volume":"47","author":"D Rigby","year":"2024","unstructured":"Rigby D. Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. Aust Prescr. 2024;47(5):140\u20137.","journal-title":"Aust Prescr"},{"issue":"2","key":"3512_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jaip.2020.09.026","volume":"9","author":"J Haughney","year":"2021","unstructured":"Haughney J, Lee AJ, McKnight E, et al. Peak inspiratory flow measured at different inhaler resistances in patients with asthma. J Allergy Clin Immunol Pract. 2021;9(2):890\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.026.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"3512_CR26","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s12325-023-02585-z","volume":"40","author":"P Daley-Yates","year":"2023","unstructured":"Daley-Yates P, Singh D, Igea JM, et al. Assessing the effects of changing patterns of inhaled corticosteroid dosing and adherence with fluticasone furoate and budesonide on asthma management. Adv Ther. 2023;40(9):4042\u201359. https:\/\/doi.org\/10.1007\/s12325-023-02585-z.","journal-title":"Adv Ther"},{"issue":"2","key":"3512_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bcp.14406","volume":"87","author":"P Daley-Yates","year":"2021","unstructured":"Daley-Yates P, Brealey N, Thomas S, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87(2):483\u201393. https:\/\/doi.org\/10.1111\/bcp.14406.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3512_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","volume":"5","author":"JD Blakey","year":"2017","unstructured":"Blakey JD, Price DB, Pizzichini E, et al. Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group Initiative. J Allergy Clin Immunol Pract. 2017;5(4):1015-24.e8. https:\/\/doi.org\/10.1016\/j.jaip.2016.11.007.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"3512_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/thoraxjnl-2015-208138","volume":"71","author":"RJ Loymans","year":"2016","unstructured":"Loymans RJ, Honkoop PJ, Termeer EH, et al. Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. Thorax. 2016;71(9):838\u201346. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-208138.","journal-title":"Thorax"},{"issue":"11","key":"3512_CR30","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1111\/bcp.15801","volume":"89","author":"S Oosterholt","year":"2023","unstructured":"Oosterholt S, Pavord ID, Brusselle G, et al. Modelling ASthma TrEatment Responses (MASTER): effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol. 2023;89(11):3273\u201390. https:\/\/doi.org\/10.1111\/bcp.15801.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"3512_CR31","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1007\/s12325-024-02914-w","volume":"41","author":"G Garcia","year":"2024","unstructured":"Garcia G, van Dijkman SC, Pavord I, et al. A simulation study of the effect of clinical characteristics and treatment choice on reliever medication use, symptom control and exacerbation risk in moderate-severe asthma. Adv Ther. 2024;41(8):3196\u2013216. https:\/\/doi.org\/10.1007\/s12325-024-02914-w.","journal-title":"Adv Ther"},{"key":"3512_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1753466619884532","volume":"13","author":"F Lavorini","year":"2019","unstructured":"Lavorini F, Janson C, Braido F, Stratelis G, L\u00f8kke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532. https:\/\/doi.org\/10.1177\/1753466619884532.","journal-title":"Ther Adv Respir Dis"},{"key":"3512_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.rmed.2017.09.010","volume":"132","author":"H Svedsater","year":"2017","unstructured":"Svedsater H, Leather D, Robinson T, et al. Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys. Respir Med. 2017;132:76\u201383. https:\/\/doi.org\/10.1016\/j.rmed.2017.09.010.","journal-title":"Respir Med"},{"issue":"1","key":"3512_CR34","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00497-2020","volume":"7","author":"VL Clark","year":"2021","unstructured":"Clark VL, Gibson PG, McDonald VM. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. ERJ Open Res. 2021;7(1):00497-2020. https:\/\/doi.org\/10.1183\/23120541.00497-2020.","journal-title":"ERJ Open Res"},{"issue":"8","key":"3512_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037491","volume":"10","author":"C Baggott","year":"2020","unstructured":"Baggott C, Chan A, Hurford S, et al. Patient preferences for asthma management: a qualitative study. BMJ Open. 2020;10(8):e037491. https:\/\/doi.org\/10.1136\/bmjopen-2020-037491.","journal-title":"BMJ Open"},{"issue":"2","key":"3512_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4104\/pcrj.2013.00017","volume":"22","author":"D Price","year":"2013","unstructured":"Price D, Lee AJ, Sims EJ, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J. 2013;22(2):161\u20138. https:\/\/doi.org\/10.4104\/pcrj.2013.00017.","journal-title":"Prim Care Respir J"},{"issue":"2","key":"3512_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaci.2003.10.011","volume":"113","author":"SW Stoloff","year":"2004","unstructured":"Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113(2):245\u201351. https:\/\/doi.org\/10.1016\/j.jaci.2003.10.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3512_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/s0149-2918(02)85026-3","volume":"24","author":"M Iskedjian","year":"2002","unstructured":"Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24(2):302\u201316. https:\/\/doi.org\/10.1016\/s0149-2918(02)85026-3.","journal-title":"Clin Ther"},{"key":"3512_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/ppa.S234651","volume":"14","author":"S Amin","year":"2020","unstructured":"Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Understanding patient perspectives on medication adherence in asthma: a targeted review of qualitative studies. Patient Prefer Adherence. 2020;14:541\u201351. https:\/\/doi.org\/10.2147\/ppa.S234651.","journal-title":"Patient Prefer Adherence"},{"key":"3512_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107714","volume":"231","author":"S Packham","year":"2024","unstructured":"Packham S, \u00d6dling M, Bossios A, Konradsen JR, Stridsman C. Adherence to inhaled corticosteroid therapy and treatment escalation in the Swedish adult asthma population. Respir Med. 2024;231:107714. https:\/\/doi.org\/10.1016\/j.rmed.2024.107714.","journal-title":"Respir Med"},{"key":"3512_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03332-2","author":"JK Quint","year":"2025","unstructured":"Quint JK, Rendon A, Stanford R, et al. Identifying treatable traits of patients with asthma prescribed an ICS\/LABA: a descriptive analytic database study in England. Adv Ther. 2025;42:5164\u20136. https:\/\/doi.org\/10.1007\/s12325-025-03332-2.","journal-title":"Adv Ther"},{"issue":"6","key":"3512_CR42","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2011.09.011","volume":"128","author":"LK Williams","year":"2011","unstructured":"Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185-91.e2. https:\/\/doi.org\/10.1016\/j.jaci.2011.09.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3512_CR43","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s12325-024-02823-y","volume":"41","author":"PT Daley-Yates","year":"2024","unstructured":"Daley-Yates PT, Aggarwal B, Plank M. Pharmacological basis of differences in dose response, dose equivalence, and duration of action of inhaled corticosteroids. Adv Ther. 2024;41(1):1995\u20132009. https:\/\/doi.org\/10.1007\/s12325-024-02823-y.","journal-title":"Adv Ther"},{"issue":"1","key":"3512_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01246-z","volume":"20","author":"J Schreiber","year":"2020","unstructured":"Schreiber J, Sonnenburg T, Luecke E. Inhaler devices in asthma and COPD patients \u2013 a prospective cross-sectional study on inhaler preferences and error rates. BMC Pulm Med. 2020;20(1):222. https:\/\/doi.org\/10.1186\/s12890-020-01246-z.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3512_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/resp.14852","volume":"30","author":"DF Wurzel","year":"2025","unstructured":"Wurzel DF, Montgomery BD, Anderson N, et al. Environmental impact of inhaled medicines: a Thoracic Society of Australia and New Zealand position statement. Respirology. 2025;30(2):101\u201312.","journal-title":"Respirology"},{"issue":"1","key":"3512_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/20018525.2021.1891725","volume":"8","author":"CS Ulrik","year":"2021","unstructured":"Ulrik CS, Lange P, Hilberg O. Fractional exhaled nitric oxide as a determinant for the clinical course of asthma: a systematic review. Eur Clin Respir J. 2021;8(1):1891725. https:\/\/doi.org\/10.1080\/20018525.2021.1891725.","journal-title":"Eur Clin Respir J"},{"issue":"2","key":"3512_CR47","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2023.0020","volume":"7","author":"P Pfeffer","year":"2023","unstructured":"Pfeffer P, Hajmohammadi H, Cole J, et al. Characteristics of patients with asthma overprescribed short-acting beta-agonist (SABA) reliever inhalers stratified by blood eosinophil count in North East London: a cross-sectional observational study. BJGP Open. 2023;7(2):BJGPO.2023.0020. https:\/\/doi.org\/10.3399\/BJGPO.2023.0020.","journal-title":"BJGP Open"},{"issue":"11","key":"3512_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849\u201358. https:\/\/doi.org\/10.1016\/s2213-2600(15)00367-7.","journal-title":"Lancet Respir Med"},{"key":"3512_CR49","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2147\/jaa.S306416","volume":"14","author":"TN Tran","year":"2021","unstructured":"Tran TN, Kerkhof M, Carter V, Price DB. Persistence of eosinophilic asthma endotype and clinical outcomes: a real-world observational study. J Asthma Allergy. 2021;14:727\u201342. https:\/\/doi.org\/10.2147\/jaa.S306416.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"3512_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/19420862.2017.1392425","volume":"10","author":"M Godar","year":"2018","unstructured":"Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type\u00a02 asthma: current status and future prospects. MAbs. 2018;10(1):34\u201345. https:\/\/doi.org\/10.1080\/19420862.2017.1392425.","journal-title":"MAbs"},{"issue":"4","key":"3512_CR51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","volume":"199","author":"MC McGregor","year":"2019","unstructured":"McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433\u201345. https:\/\/doi.org\/10.1164\/rccm.201810-1944CI.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3512_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/2045-7022-3-37","volume":"3","author":"D Price","year":"2013","unstructured":"Price D, Ryan D, Burden A, et al. Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. Clin Transl Allergy. 2013;3(1):37. https:\/\/doi.org\/10.1186\/2045-7022-3-37.","journal-title":"Clin Transl Allergy"},{"issue":"8","key":"3512_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13081428","volume":"13","author":"N Murugesan","year":"2023","unstructured":"Murugesan N, Saxena D, Dileep A, Adrish M, Hanania NA. Update on the role of FeNO in asthma management. Diagnostics (Basel). 2023;13(8):1428. https:\/\/doi.org\/10.3390\/diagnostics13081428.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"3512_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-025-00418-w","volume":"35","author":"G Lewis","year":"2025","unstructured":"Lewis G, Morton K, Santillo M, et al. Qualitative insights into planning implementation of FeNO-guided asthma management in primary care. NPJ Prim Care Respir Med. 2025;35(1):16.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3512_CR55","unstructured":"The Health and Innovation Network. Improving access to FENO testing in primary care. 2025. https:\/\/thehealthinnovationnetwork.co.uk\/our-programmes\/respiratory-disease\/bettering-access-to-feno-testing-in-primary-care\/. Accessed 17 Feb 2026."},{"key":"3512_CR56","unstructured":"Asthma UK Centre for Applied Research. Development and Evaluation of an online FeNO-guided asthma management INtervEntion in primary care (DEFINE). 2025. https:\/\/usher.ed.ac.uk\/aukcar\/knowledge-hub\/projects\/define. Accessed 17 Feb 2026."},{"issue":"737","key":"3512_CR57","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3399\/bjgp23X735813","volume":"73","author":"K Wang","year":"2023","unstructured":"Wang K, Stonham C, Rutherford C, Pavord ID. Fractional exhaled nitric oxide (FeNO): the future of asthma care? Br J Gen Pract. 2023;73(737):565\u20138. https:\/\/doi.org\/10.3399\/bjgp23X735813.","journal-title":"Br J Gen Pract"},{"key":"3512_CR58","unstructured":"US Food and Drug Administration. BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/204275s017lbl.pdf. Accessed 17 Feb 2026."},{"key":"3512_CR59","unstructured":"US Food and Drug Administration. SYMBICORT prescribing information 2010. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021929s021lbl.pdf. Accessed 17 Feb 2026."},{"key":"3512_CR60","unstructured":"US Food and Drug Administration. ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder) prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021077s061lbl.pdf. Accessed 17 Feb 2026."},{"key":"3512_CR61","unstructured":"Electronics Medicines Compendium. FOSTAIR 100\/6 micrograms per actuation pressurised inhalation solution. 2023. https:\/\/www.medicines.org.uk\/emc\/product\/6318\/smpc\/print. Accessed 17 Feb 2026."},{"issue":"10109","key":"3512_CR62","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/s0140-6736(17)32397-8","volume":"390","author":"A Woodcock","year":"2017","unstructured":"Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390(10109):2247\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(17)32397-8.","journal-title":"Lancet"},{"key":"3512_CR63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.rmed.2018.06.009","volume":"141","author":"P Devillier","year":"2018","unstructured":"Devillier P, Humbert M, Boye A, et al. Efficacy and safety of once-daily fluticasone furoate\/vilanterol (FF\/VI) versus twice-daily inhaled corticosteroids\/long-acting \u03b2(2)-agonists (ICS\/LABA) in patients with uncontrolled asthma: an open-label, randomized, controlled trial. Respir Med. 2018;141:111\u201320. https:\/\/doi.org\/10.1016\/j.rmed.2018.06.009.","journal-title":"Respir Med"},{"issue":"21","key":"3512_CR64","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1901963.","journal-title":"N Engl J Med"},{"key":"3512_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107478","volume":"221","author":"N Roche","year":"2024","unstructured":"Roche N, Yorganc\u0131o\u011flu A, Cruz AA, et al. Systematic literature review of traits and outcomes reported in randomised controlled trials of asthma with regular dosing of inhaled corticosteroids with short-acting \u03b2(2)-agonist reliever, as-needed ICS\/formoterol, or ICS\/formoterol maintenance and reliever therapy. Respir Med. 2024;221:107478. https:\/\/doi.org\/10.1016\/j.rmed.2023.107478.","journal-title":"Respir Med"},{"issue":"2","key":"3512_CR66","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00248-2022","volume":"9","author":"Y Lee","year":"2023","unstructured":"Lee Y, Lee JH, Park SY, et al. Roles of real-world evidence in severe asthma treatment: challenges and opportunities. ERJ Open Res. 2023;9(2):00248-2022. https:\/\/doi.org\/10.1183\/23120541.00248-2022.","journal-title":"ERJ Open Res"},{"key":"3512_CR67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/jaa.s517932","volume":"18","author":"A Gogali","year":"2025","unstructured":"Gogali A, Rovina N, Samitas K, et al. Real-life effectiveness of budesonide\/formoterol as maintenance and reliever treatment via the Elpenhaler\u00ae Device in patients with asthma: the NOTOS Observational Study. J Asthma Allergy. 2025;18:605\u201318. https:\/\/doi.org\/10.2147\/jaa.s517932.","journal-title":"J Asthma Allergy"},{"issue":"7","key":"3512_CR68","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1080\/02770903.2018.1490751","volume":"56","author":"L Jacques","year":"2019","unstructured":"Jacques L, Bakerly ND, New JP, et al. Effectiveness of fluticasone furoate\/vilanterol versus fluticasone propionate\/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56(7):748\u201357. https:\/\/doi.org\/10.1080\/02770903.2018.1490751.","journal-title":"J Asthma"},{"issue":"4","key":"3512_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053964","volume":"12","author":"A Sicras-Mainar","year":"2022","unstructured":"Sicras-Mainar A, G\u00f3mez Rodr\u00edguez B, Traseira-Lugilde S, Fern\u00e1ndez-S\u00e1nchez T, Velasco Garrido JL. Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study. BMJ Open. 2022;12(4):e053964. https:\/\/doi.org\/10.1136\/bmjopen-2021-053964.","journal-title":"BMJ Open"},{"issue":"1","key":"3512_CR70","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/02770903.2019.1663429","volume":"58","author":"CM Averell","year":"2021","unstructured":"Averell CM, Stanford RH, Lalibert\u00e9 F, et al. Medication adherence in patients with asthma using once-daily versus twice-daily ICS\/LABAs. J Asthma. 2021;58(1):102\u201311. https:\/\/doi.org\/10.1080\/02770903.2019.1663429.","journal-title":"J Asthma"},{"issue":"6","key":"3512_CR71","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s12325-020-01344-8","volume":"37","author":"M Parimi","year":"2020","unstructured":"Parimi M, Svedsater H, Ann Q, et al. Persistence and adherence to ICS\/LABA drugs in UK patients with asthma: a retrospective new-user cohort study. Adv Ther. 2020;37(6):2916\u201331. https:\/\/doi.org\/10.1007\/s12325-020-01344-8.","journal-title":"Adv Ther"},{"key":"3512_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s40248-018-0131-x","volume":"13","author":"RW Dal Negro","year":"2018","unstructured":"Dal Negro RW, Bonadiman L, Turco P. Fluticasone furoate\/vilanterol 92\/22\u00a0\u03bcg once-a-day vs beclomethasone dipropionate\/formoterol 100\/6\u00a0\u03bcg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma. Multidiscip Respir Med. 2018;13:18. https:\/\/doi.org\/10.1186\/s40248-018-0131-x.","journal-title":"Multidiscip Respir Med"},{"issue":"10202","key":"3512_CR73","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","volume":"394","author":"J Hardy","year":"2019","unstructured":"Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)31948-8.","journal-title":"Lancet"},{"issue":"3","key":"3512_CR74","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1752-699x.2010.00217.x","volume":"5","author":"U S\u00f8es-Petersen","year":"2011","unstructured":"S\u00f8es-Petersen U, Kava T, Dahle R, Lei Y, Dam N. Budesonide\/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted \u201creal life\u201d setting. Clin Respir J. 2011;5(3):173\u201382. https:\/\/doi.org\/10.1111\/j.1752-699x.2010.00217.x.","journal-title":"Clin Respir J"},{"key":"3512_CR75","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2147\/jaa.s358798","volume":"15","author":"R Ulmeanu","year":"2022","unstructured":"Ulmeanu R, Bloju S, Vittos O. Assessment of symptoms control, pulmonary function and related quality of life in asthmatic patients treated with extrafine beclomethasone dipropionate\/formoterol fumarate 100\/6 \u03bcg pMDI: results of a multicenter observational study in Romania (ALFRESCO study). J Asthma Allergy. 2022;15:919\u201333. https:\/\/doi.org\/10.2147\/jaa.s358798.","journal-title":"J Asthma Allergy"},{"key":"3512_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/1753466618796987","volume":"12","author":"V Backer","year":"2018","unstructured":"Backer V, Ellery A, Borzova S, et al. Non-interventional study of the safety and effectiveness of fluticasone propionate\/formoterol fumarate in real-world asthma management. Ther Adv Respir Dis. 2018;12:1753466618796987. https:\/\/doi.org\/10.1177\/1753466618796987.","journal-title":"Ther Adv Respir Dis"},{"key":"3512_CR77","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221137272","volume":"16","author":"S Balamurugan","year":"2022","unstructured":"Balamurugan S, Sonia D, Vikrant D, et al. Effectiveness and safety of salmeterol\/fluticasone fixed-dose combination delivered through Synchrobreathe(\u00ae) in patients with asthma: the real-world EVOLVE study. Ther Adv Respir Dis. 2022;16:17534666221137272. https:\/\/doi.org\/10.1177\/17534666221137272.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"3512_CR78","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4104\/pcrj.2011.00090","volume":"21","author":"RA Riemersma","year":"2012","unstructured":"Riemersma RA, Postma D, van der Molen T. Budesonide\/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J. 2012;21(1):50\u20136. https:\/\/doi.org\/10.4104\/pcrj.2011.00090.","journal-title":"Prim Care Respir J"},{"issue":"1","key":"3512_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03190-8","volume":"24","author":"WC Huang","year":"2024","unstructured":"Huang WC, Cheng WC, Chen CY, et al. Comparison of budesonide\/formoterol versus fluticasone furoate\/vilanterol as maintenance and reliever therapy for asthma control: a real-world observational study. BMC Pulm Med. 2024;24(1):374. https:\/\/doi.org\/10.1186\/s12890-024-03190-8.","journal-title":"BMC Pulm Med"},{"key":"3512_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1874306401408010059","volume":"8","author":"D Pandya","year":"2014","unstructured":"Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014;8:59\u201365. https:\/\/doi.org\/10.2174\/1874306401408010059.","journal-title":"Open Respir Med J"},{"issue":"3","key":"3512_CR81","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1081-1206(10)60711-9","volume":"98","author":"GS Rachelefsky","year":"2007","unstructured":"Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007;98(3):225\u201338. https:\/\/doi.org\/10.1016\/S1081-1206(10)60711-9.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3512_CR82","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2174\/1874306401408010093","volume":"8","author":"V Sannarangappa","year":"2014","unstructured":"Sannarangappa V, Jalleh R. Inhaled corticosteroids and secondary adrenal insufficiency. Open Respir Med J. 2014;8:93\u2013100. https:\/\/doi.org\/10.2174\/1874306401408010093.","journal-title":"Open Respir Med J"},{"issue":"1","key":"3512_CR83","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1183\/09031936.00080912","volume":"42","author":"F Lapi","year":"2012","unstructured":"Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J. 2012;42(1):79\u201386. https:\/\/doi.org\/10.1183\/09031936.00080912.","journal-title":"Eur Respir J"},{"issue":"3","key":"3512_CR84","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcp.12637","volume":"80","author":"PT Daley-Yates","year":"2015","unstructured":"Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372\u201380. https:\/\/doi.org\/10.1111\/bcp.12637.","journal-title":"Br J Clin Pharmacol"},{"key":"3512_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03407-0","author":"A Woodcock","year":"2025","unstructured":"Woodcock A, Blakey J, Bourdin A, et al. Correction to: Real-world comparative effectiveness study in patients with asthma initiating fluticasone furoate\/vilanterol or beclometasone dipropionate\/ formoterol fumarate in general practice in England. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03407-0.","journal-title":"Adv Ther"},{"key":"3512_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-025-00325-y","author":"A Woodcock","year":"2025","unstructured":"Woodcock A, Blakey J, Bourdin A, et al. Correction: real-world comparative effectiveness in patients with asthma newly initiating fluticasone furoate\/vilanterol or budesonide\/formoterol: a United Kingdom general practice cohort study. Pulm Ther. 2025. https:\/\/doi.org\/10.1007\/s41030-025-00325-y.","journal-title":"Pulm Ther"},{"issue":"9","key":"3512_CR87","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1080\/02770903.2021.1963767","volume":"59","author":"CM Averell","year":"2022","unstructured":"Averell CM, Lalibert\u00e9 F, Germain G, et al. Symptom control in patients with asthma using inhaled corticosteroids\/long-acting \u03b2(2)-agonists (fluticasone furoate\/vilanterol or budesonide\/formoterol) in the US: a retrospective matched cohort study. J Asthma. 2022;59(9):1805\u201318. https:\/\/doi.org\/10.1080\/02770903.2021.1963767.","journal-title":"J Asthma"},{"key":"3512_CR88","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221116997","volume":"16","author":"CM Averell","year":"2022","unstructured":"Averell CM, Lalibert\u00e9 F, Germain G, et al. Impact of adherence to treatment with inhaled corticosteroids\/long-acting \u03b2-agonists on asthma outcomes in the United States. Ther Adv Respir Dis. 2022;16:17534666221116997. https:\/\/doi.org\/10.1177\/17534666221116997.","journal-title":"Ther Adv Respir Dis"},{"key":"3512_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108172","volume":"245","author":"NA Hanania","year":"2025","unstructured":"Hanania NA, Stanford R, Rendon A, et al. Comparative effectiveness of inhaled fluticasone propionate\/salmeterol and budesonide\/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025;245:108172. https:\/\/doi.org\/10.1016\/j.rmed.2025.108172.","journal-title":"Respir Med"},{"issue":"1","key":"3512_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-024-00402-w","volume":"35","author":"S Zhang","year":"2025","unstructured":"Zhang S, Czira A, Harley J, et al. Burden of illness among patients with asthma prescribed inhaled corticosteroids\/long-acting \u03b2(2)-agonists. NPJ Prim Care Respir Med. 2025;35(1):10. https:\/\/doi.org\/10.1038\/s41533-024-00402-w.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"1","key":"3512_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-023-00336-9","volume":"33","author":"S Zhang","year":"2023","unstructured":"Zhang S, White J, Hunter AG, et al. Suboptimally controlled asthma in patients treated with inhaled ICS\/LABA: prevalence, risk factors, and outcomes. NPJ Prim Care Respir Med. 2023;33(1):19. https:\/\/doi.org\/10.1038\/s41533-023-00336-9.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"10","key":"3512_CR92","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jaip.2022.06.009","volume":"10","author":"C Kim","year":"2022","unstructured":"Kim C, Lee Y, Lee E, et al. Effectiveness of maintenance and reliever therapy using inhaled corticosteroid formoterol in asthmatics. J Allergy Clin Immunol Pract. 2022;10(10):2638-45.e3. https:\/\/doi.org\/10.1016\/j.jaip.2022.06.009.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"3512_CR93","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","volume":"56","author":"J Davis","year":"2019","unstructured":"Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS\/LABA: a real-world study. J Asthma. 2019;56(3):332\u201340. https:\/\/doi.org\/10.1080\/02770903.2018.1455858.","journal-title":"J Asthma"},{"key":"3512_CR94","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.rmed.2017.04.004","volume":"127","author":"J Lin","year":"2017","unstructured":"Lin J, Li J, Yu W, et al. A multicenter, cross-sectional, observational study of budesonide\/formoterol maintenance and reliever therapy in real-world settings. Respir Med. 2017;127:45\u201350. https:\/\/doi.org\/10.1016\/j.rmed.2017.04.004.","journal-title":"Respir Med"},{"issue":"2","key":"3512_CR95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.20452\/pamw.3899","volume":"127","author":"B Rogala","year":"2017","unstructured":"Rogala B, Majak P, Gl\u00fcck J, D\u0119bowski T. Asthma control in adult patients treated with a combination of inhaled corticosteroids and long\u2011acting \u03b22\u2011agonists: a prospective observational study. Pol Arch Intern Med. 2017;127(2):100\u20136. https:\/\/doi.org\/10.20452\/pamw.3899.","journal-title":"Pol Arch Intern Med"},{"issue":"11","key":"3512_CR96","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.18553\/jmcp.2015.21.11.1014","volume":"21","author":"RH Stanford","year":"2015","unstructured":"Stanford RH, Nagar S, Lin X, O\u2019Connor RD. Use of ICS\/LABA on asthma exacerbation risk in patients within a medical group. J Manag Care Spec Pharm. 2015;21(11):1014\u20139. https:\/\/doi.org\/10.18553\/jmcp.2015.21.11.1014.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03512-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:45Z","timestamp":1778229465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03512-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3512"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03512-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John Blakey reports, in the last 3\u00a0years, personal and institutional consulting fees or payment for educational activities from AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi, and GSK; support for attending meetings and\/or travel from AstraZeneca and GSK; receipt of medical writing support from GSK and Teva; payment to their institution for advisory work from Asthma Australia. Lorenzo Cecchi reports consulting fees from GSK and Novartis; honoraria for lectures from AstraZeneca, Chiesi, Menarini, Novartis, Sanofi, Thermofisher, and GSK; support for attending meetings from Menarini; grants for scientific boards from GSK, FIRMA, Menarini, and Thermofisher. Christian Domingo declares having received financial aid for travel support and speakers\u2019 bureaus from ALK-Abello, Allergy Therapeutics, AstraZeneca, Chiesi, GSK, Hall Allergy, Inmunotek, Menarini Diagnostics, MSD, Novartis, Roxall, Sanofi, and Stallergenes. Tony D\u2019Urzo has received research, consulting and lecturing fees from AstraZeneca, COVIS Pharma Canada, GSK, Sanofigenzyme, TEVA Canada, and Valeopharma Canada. Dave Singh has received sponsorship to attend and speak at international meetings, honoraria for lecturing or attending advisory boards from Adovate, Almirall, Anaveon, Apogee, Arcutis Biotherapeutics, Arrowhead, AstraZeneca, Belenos Biosciences, Bial, Celldex, Chiesi, Cipla, CONNECT Biopharm, Covis, DevPro Biopharma LCC, Elpen, Empirico, EpiEndo, Generate Biomedicines, GlaxoSmithKline, Glenmark, Jasper, Kinaset Therapeutics, KOLON, Kymera, Lupin, Melodia, Menarini, MicroA, OM Pharma, OrientEuroPharma, Recipharm, Revolo, RIGImmune Inc, Roche, Roivant Sciences, Sanofi, Sitryx, Synairgen, Tetherex, UCB, Upstream, Verona Pharma, Winward, Zura Bio, Zymeworks. Manish Verma is a GSK employee and holds financial equities in GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}